The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
|Articles|May 10, 2017
Avantor Expands cGMP Product Portfolio
Author(s)Pharmaceutical Technology Editors
The company will display its expanded supply chain product portfolio at CPhI North America 2017.
Advertisement
Avantor will feature its expanded cGMP manufacturing capabilities at CPhI North America from May 16–18, 2017. The company’s cGMP manufacturing footprint includes three North America production centers, cGMP capabilities in Gliwice, Poland, and a new cGMP manufacturing and packaging area in Panoli, India.
During the conference, several Avantor technologies will be on display including the company’s JT Baker Direct Dispense packaging platform, which delivers free-flowing performance chemicals directly to the biopharmaceutical process to minimize contamination risk. The JT Baker Bakerbond Process Chromatography Media and the company’s portfolio of cGMP materials, including excipients, salts, sugars, solvents, and solutions, will also be on display.
Source: Avantor
Advertisement
Related to this article
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
USP 1074 Revises Excipient Safety: AAPS PharmSci 360 2026
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
AI Formulation: Regulators Want Data
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5